deltatrials
Completed PHASE2 INTERVENTIONAL NCT00462852

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]

Sponsor: Hull University Teaching Hospitals NHS Trust

Conditions Pancreatic Cancer Thromboembolism
Interventions dalteparin diagnostic laboratory biomarker analysis gemcitabine hydrochloride
Updated 6 times since 2017 Last updated: Aug 9, 2013 Started: Apr 30, 2003 Completion: Nov 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer and Thromboembolism and is currently completed. Hull University Teaching Hospitals NHS Trust leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotCompleted~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hull University Teaching Hospitals NHS Trust
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations